天演药业上涨20.61%，报1.99美元/股，总市值9379.12万美元

Core Viewpoint - Tianyan Pharmaceuticals (ADAG) experienced a significant stock price increase of 20.61%, reaching $1.99 per share, with a total market capitalization of $93.79 million as of August 14 [1] Financial Performance - As of December 31, 2024, Tianyan Pharmaceuticals reported total revenue of $103,200, representing a year-over-year decrease of 99.43% [1] - The company recorded a net loss attributable to shareholders of $33.42 million, a decline of 76.41% compared to the previous year [1] Company Overview - Tianyan Pharmaceuticals is a biopharmaceutical company focused on the development of clinical products driven by its proprietary platform, aiming to discover and develop novel cancer immunotherapies based on original antibodies [1] - The company utilizes a powerful platform that combines computational biology and artificial intelligence to create new antibodies with high safety and efficacy, providing hope for more cancer patients [1] - The company's antibody discovery engine, known as the "Dynamic Precision Library," is advancing the development of its product pipeline, with the goal of creating potential global innovative or best-in-class products [1]